{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:36:35Z","timestamp":1762425395896,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03074-9","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:32:04Z","timestamp":1760113924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating DDIs in cancer patients receiving anticoagulants and antineoplastics: a scoping review focusing on therapeutic efficacy and safety"],"prefix":"10.1007","volume":"42","author":[{"given":"Melina","family":"Yerolatsite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigoris","family":"Gerotziafas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanteznta","family":"Torounidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Lefkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despoina","family":"Pantazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3074_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.thromres.2024.04.015","volume":"238","author":"HCM Tran","year":"2024","unstructured":"Tran HCM, Mbemba E, Mourot N, et al. The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration and the resistance to anticancer agents. Thromb Res. 2024;238:172\u201383.","journal-title":"Thromb Res"},{"key":"3074_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.thromres.2019.09.003","volume":"187","author":"R AmraneDjedidi","year":"2020","unstructured":"AmraneDjedidi R, Rousseau A, Larsen AK, et al. Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells. Thromb Res. 2020;187:170\u20139.","journal-title":"Thromb Res"},{"key":"3074_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020395","author":"C Colarusso","year":"2025","unstructured":"Colarusso C, Terlizzi M, Di Caprio S, et al. Role of the AIM2 inflammasome in cancer: potential therapeutic strategies. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13020395.","journal-title":"Biomedicines"},{"key":"3074_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost. 2023;21:1397\u2013408.","journal-title":"J Thromb Haemost"},{"key":"3074_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2019.08.009","volume":"215","author":"F Posch","year":"2020","unstructured":"Posch F, Hofer S, Thaler J, et al. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Transl Res. 2020;215:41\u201356.","journal-title":"Transl Res"},{"issue":"Suppl 1","key":"3074_CR6","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0049-3848(20)30396-0","volume":"191","author":"JT Buijs","year":"2020","unstructured":"Buijs JT, Versteeg HH. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb Res. 2020;191(Suppl 1):S43\u20139.","journal-title":"Thromb Res"},{"key":"3074_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s11864-024-01210-7","volume":"25","author":"D Pantazi","year":"2024","unstructured":"Pantazi D, Alivertis D, Tselepis AD. Underlying mechanisms of thrombosis associated with cancer and anticancer therapies. Curr Treat Options Oncol. 2024;25:897\u2013913.","journal-title":"Curr Treat Options Oncol"},{"key":"3074_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959\u201369.","journal-title":"Blood"},{"key":"3074_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","volume":"28","author":"TF Wang","year":"2023","unstructured":"Wang TF, Khorana AA, Agnelli G, et al. Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction. Oncologist. 2023;28:555\u201364.","journal-title":"Oncologist"},{"key":"3074_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100137","volume":"7","author":"M Candeloro","year":"2023","unstructured":"Candeloro M, Carlin S, Shapiro MJ, et al. Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review. Res Pract Thromb Haemost. 2023;7:100137.","journal-title":"Res Pract Thromb Haemost"},{"key":"3074_CR11","first-page":"376","volume":"8","author":"CT Doligalski","year":"2012","unstructured":"Doligalski CT, Tong Logan A, Silverman A. Drug interactions: a primer for the gastroenterologist. Gastroenterol Hepatol (N Y). 2012;8:376\u201383.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"Suppl 1","key":"3074_CR12","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","volume":"213","author":"D Pantazi","year":"2022","unstructured":"Pantazi D, Tselepis AD. Cardiovascular toxic effects of antitumor agents: pathogenetic mechanisms. Thromb Res. 2022;213(Suppl 1):S95-s102.","journal-title":"Thromb Res"},{"key":"3074_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023;34:452\u201367.","journal-title":"Ann Oncol"},{"key":"3074_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, et al. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14061120.","journal-title":"Pharmaceutics"},{"key":"3074_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytad006","volume":"7","author":"D Menichelli","year":"2023","unstructured":"Menichelli D, Pastori D, Pignatelli P, et al. Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. Eur Heart J Case Rep. 2023;7:ytad006.","journal-title":"Eur Heart J Case Rep"},{"key":"3074_CR16","first-page":"8559","volume":"30","author":"N Tsoukalas","year":"2022","unstructured":"Tsoukalas N, Brito-Dellan N, Font C, et al. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Support Care Cancer. 2022;30:8559\u201373.","journal-title":"Support Care Cancer"},{"key":"3074_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2023.10.004","volume":"231","author":"TF Wang","year":"2023","unstructured":"Wang TF, Hill M, Mallick R, et al. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies. Thromb Res. 2023;231:128\u201334.","journal-title":"Thromb Res"},{"key":"3074_CR18","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1177\/1078155220901777","volume":"26","author":"D Yassine","year":"2020","unstructured":"Yassine D, Brown EN, Putney D, et al. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting. J Oncol Pharm Pract. 2020;26:1650\u20136.","journal-title":"J Oncol Pharm Pract"},{"key":"3074_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/1078155220901569","volume":"26","author":"HK Ng","year":"2020","unstructured":"Ng HK, Rogala BG, Ades S, et al. Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. J Oncol Pharm Pract. 2020;26:1637\u201342.","journal-title":"J Oncol Pharm Pract"},{"key":"3074_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.resinv.2020.11.007","volume":"59","author":"T Hotta","year":"2021","unstructured":"Hotta T, Tsubata Y, Hamai K, et al. Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism. Respir Investig. 2021;59:327\u201334.","journal-title":"Respir Investig"},{"key":"3074_CR21","first-page":"445","volume":"12","author":"R Potdar","year":"2022","unstructured":"Potdar R, Gartrell BA, Given R, et al. Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: a post-hoc analysis of TITAN and SPARTAN studies. Am J Cancer Res. 2022;12:445\u201350.","journal-title":"Am J Cancer Res"},{"key":"3074_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11239-023-02879-7","volume":"56","author":"B Truong","year":"2023","unstructured":"Truong B, Hornsby L, Fox BI, et al. Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach. J Thromb Thrombolysis. 2023;56:555\u201367.","journal-title":"J Thromb Thrombolysis"},{"key":"3074_CR23","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1002\/cncr.34937","volume":"129","author":"H Bolek","year":"2023","unstructured":"Bolek H, \u00dcr\u00fcn Y. Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents. Cancer. 2023;129:3216\u201329.","journal-title":"Cancer"},{"key":"3074_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2014.58.7550","volume":"33","author":"G Nightingale","year":"2015","unstructured":"Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453\u20139.","journal-title":"J Clin Oncol"},{"key":"3074_CR25","volume":"45","author":"M Sebuhyan","year":"2020","unstructured":"Sebuhyan M, Crichi B, Abdallah NA, et al. Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. J Med Vasc. 2020;45:6s31-6s8.","journal-title":"J Med Vasc"},{"key":"3074_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.914842","volume":"13","author":"T Zhao","year":"2022","unstructured":"Zhao T, Li X, Chen Y, et al. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2\/3A4 and BCRP\/P-gp. Front Pharmacol. 2022;13:914842.","journal-title":"Front Pharmacol"},{"key":"3074_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010282","author":"G Grze\u015bk","year":"2020","unstructured":"Grze\u015bk G, Wo\u017aniak-Wi\u015bniewska A, B\u0142a\u017cejewski J, et al. The interactions of Nintedanib and oral anticoagulants-molecular mechanisms and clinical implications. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms22010282.","journal-title":"Int J Mol Sci"},{"key":"3074_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cpt.1434","volume":"105","author":"J Niu","year":"2019","unstructured":"Niu J, Straubinger RM, Mager DE. Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther. 2019;105:1395\u2013406.","journal-title":"Clin Pharmacol Ther"},{"key":"3074_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.6004\/jadpro.2023.14.5.7","volume":"14","author":"LK Lohr","year":"2023","unstructured":"Lohr LK, Blake KT, Chan CM, et al. Managing Drug Interactions With Oral Anticancer Treatments. J Adv Pract Oncol. 2023;14:419\u201338.","journal-title":"J Adv Pract Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:33:19Z","timestamp":1762425199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03074-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}],"article-number":"511"}}